Northwest Biotherapeutics (STU:NBYB) Investments And Advances : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Northwest Biotherapeutics Investments And Advances?

Northwest Biotherapeutics's Investments And Advances for the quarter that ended in Sep. 2024 was €0.00 Mil.

Northwest Biotherapeutics Investments And Advances Historical Data

The historical data trend for Northwest Biotherapeutics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Investments And Advances Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

Northwest Biotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Investments And Advances	Get a 7-Day Free Trial															-	-	-	-	-

Northwest Biotherapeutics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Northwest Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (STU:NBYB) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

NWBO:USA

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics Headlines

No Headlines